These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1913 related items for PubMed ID: 22537989

  • 1. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.
    Vaccine; 2012 Jul 06; 30(32):4884-91. PubMed ID: 22537989
    [Abstract] [Full Text] [Related]

  • 2. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C, Haijema BJ, Meijerhof T, Voorn P, de Haan A, Leenhouts K, van Roosmalen ML, van Eden W, Broere F.
    Vaccine; 2014 May 19; 32(24):2904-10. PubMed ID: 24598720
    [Abstract] [Full Text] [Related]

  • 3. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH, Byun YH, Nguyen CT, Kim SY, Seong BL, Park S, Woo GJ, Yoon Y, Koh JT, Fujihashi K, Rhee JH, Lee SE.
    Vaccine; 2012 Jan 05; 30(2):466-74. PubMed ID: 22051136
    [Abstract] [Full Text] [Related]

  • 4. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H.
    J Med Virol; 2010 Jan 05; 82(1):128-37. PubMed ID: 19950232
    [Abstract] [Full Text] [Related]

  • 5. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 6. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W.
    Vaccine; 2008 Dec 02; 26(51):6555-63. PubMed ID: 18848856
    [Abstract] [Full Text] [Related]

  • 7. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
    Maltais AK, Stittelaar KJ, Veldhuis Kroeze EJ, van Amerongen G, Dijkshoorn ML, Krestin GP, Hinkula J, Arwidsson H, Lindberg A, Osterhaus AD.
    Vaccine; 2014 May 30; 32(26):3307-15. PubMed ID: 24690149
    [Abstract] [Full Text] [Related]

  • 8. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
    Petersson P, Hedenskog M, Alves D, Brytting M, Schröder U, Linde A, Lundkvist A.
    Vaccine; 2010 Sep 07; 28(39):6491-7. PubMed ID: 20637767
    [Abstract] [Full Text] [Related]

  • 9. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
    Saluja V, Visser MR, Ter Veer W, van Roosmalen ML, Leenhouts K, Hinrichs WL, Huckriede A, Frijlink HW.
    Vaccine; 2010 Nov 23; 28(50):7963-9. PubMed ID: 20946860
    [Abstract] [Full Text] [Related]

  • 10. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V, Chichester JA, Ebensen T, Schwarz K, Hartman CE, Shoji Y, Guzmán CA, Yusibov V, Sewald K, Braun A.
    Vaccine; 2014 May 30; 32(26):3216-22. PubMed ID: 24731807
    [Abstract] [Full Text] [Related]

  • 11. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z, Chen Q, Fang F, Zheng M, Chen Z.
    Vaccine; 2010 Nov 10; 28(48):7690-8. PubMed ID: 20870054
    [Abstract] [Full Text] [Related]

  • 12. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK, Tomar P, Sharma V, Dixit VK.
    Vaccine; 2011 Nov 08; 29(48):9026-37. PubMed ID: 21939718
    [Abstract] [Full Text] [Related]

  • 13. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M, Zhao Y, Nobusawa E, Nakajima S, Nakajima K, Yasuda Y, Matsui H, Hasegawa T, Maeyama J, Morokuma K, Ohkuma K, Tochikubo K.
    Microbiol Immunol; 2008 Feb 08; 52(2):55-63. PubMed ID: 18380802
    [Abstract] [Full Text] [Related]

  • 14. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, Chen Z.
    Arch Virol; 2010 Apr 08; 155(4):535-44. PubMed ID: 20195654
    [Abstract] [Full Text] [Related]

  • 15. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
    Ann J, Samant M, Rheaume C, Dumas C, Beaulieu E, Morasse A, Mallett C, Hamelin ME, Papadopoulou B, Boivin G.
    Vaccine; 2014 Sep 29; 32(43):5730-9. PubMed ID: 25173481
    [Abstract] [Full Text] [Related]

  • 16. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Moriyama M, Chiba J, Komase K, Suzuki Y, Kurata T, Sata T, Hasegawa H.
    J Med Virol; 2006 Jul 29; 78(7):954-63. PubMed ID: 16721854
    [Abstract] [Full Text] [Related]

  • 17. Intranasal co-administration of 1,8-cineole with influenza vaccine provide cross-protection against influenza virus infection.
    Li Y, Xu YL, Lai YN, Liao SH, Liu N, Xu PP.
    Phytomedicine; 2017 Oct 15; 34():127-135. PubMed ID: 28899494
    [Abstract] [Full Text] [Related]

  • 18. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
    Proudfoot O, Esparon S, Tang CK, Laurie K, Barr I, Pietersz G.
    BMC Infect Dis; 2015 Feb 26; 15():101. PubMed ID: 25887952
    [Abstract] [Full Text] [Related]

  • 19. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.
    Vaccine; 2006 May 01; 24(18):3990-4006. PubMed ID: 16516356
    [Abstract] [Full Text] [Related]

  • 20. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H.
    Vaccine; 2009 Oct 23; 27(45):6276-9. PubMed ID: 19840660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 96.